A study from Professor Colin Goding\u2019s group gives insight into the function of the BRN2 transcription factor in promoting melanoma initiation and metastasis.
Clinicians and engineers in Oxford have begun using artificial intelligence alongside endoscopy to get more accurate readings of the pre-cancerous condition Barrett\u2019s oesophagus and so determine patients most at risk of developing cancer.
Professor Yang Shi\u2019s group demonstrates that combining drugs targeting epigenetic and metabolic pathways can overcome the arrest of white blood cell differentiation in this blood cancer.
A multidisciplinary team, comprising Ludwig Oxford\u2019s Professor Jens Rittscher with Andrea Chatrian, Dr Richard Colling, Professor Clare Verrill and colleagues, develops an algorithm for automated requesting of additional investigation in diagnostically uncertain prostate biopsies.
On 28-29th April 2021, we heard the latest developments from international leaders in these fields from the University of Oxford, Ludwig Cancer Research and beyond.
Dr Chunxiao Song\u2019s team build on its TAPS method to develop an alternative to costly whole-genome sequencing for the detection of DNA methylation.
Activation of hypoxia inducible factors (HIFs) by either hypoxia or drug treatment inhibits SARS-CoV-2 entry and replication in lung epithelial cells, raising the potential of using clinically licensed HIF activators to prevent and/or treat COVID-19.
Dr Pedro Moura Alves has developed a microscale thermophoresis-based approach for rapidly and robustly analysing aryl hydrocarbon receptor interactions.
Dr Benjamin Schuster-B\u00f6ckler wins funding to develop algorithms that can identify both genetic variation and DNA methylation from the same sequencing data, with applications in biomedical research and detection of diseases such as cancer.
![\"Melanoma](\"https://www.ludwig.ox.ac.uk/news/understanding-the-role-of-brn2-in-melanoma/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n